25.1 Classification of Contrast Agents: Osmolality, Viscosity & Iodine Concentration

25.1 Classification of Contrast Agents: Osmolality, Viscosity & Iodine Concentration

Introduction to Radiopaque Contrast Media (ROCM)

In diagnostic radiography and fluoroscopy, soft tissue structures such as blood vessels, renal parenchyma, liver, and gastrointestinal mucosa often exhibit subject contrast that is too low to be distinguished from surrounding anatomic structures. Radiopaque Contrast Media (ROCM) are pharmacological compounds introduced into the body to alter the absorption coefficient of specific tissues, temporarily enhancing subject contrast and allowing visualization of physiological processes and lumen morphology.

The clinical selection of a contrast agent requires the radiologic technologist (RadTech) to balance diagnostic efficacy against potential patient toxicity, osmolality, chemical structure, and renal clearance dynamics.

---

Positive vs. Negative Contrast Agents

Contrast agents are broadly categorized into positive contrast agents and negative contrast agents based on their physical density, atomic number, and interaction with diagnostic X-ray beams.

+-------------------------------------------------------------------------+
|                         CONTRAST AGENTS SPECTRUM                        |
+------------------------------------+------------------------------------+
|     POSITIVE CONTRAST AGENTS       |     NEGATIVE CONTRAST AGENTS       |
|  - High Atomic Number (Z)          |  - Low Atomic Number (Z)           |
|  - High Physical Density           |  - Low Physical Density            |
|  - Absorbs X-rays (Photoelectric)  |  - Transmits X-rays Easily          |
|  - Radiopaque (White on Image)     |  - Radiolucent (Black on Image)    |
|  - Examples: Iodine (Z=53),        |  - Examples: Air (Z=7.6), CO2,     |
|    Barium (Z=56)                   |    Oxygen                          |
+------------------------------------+------------------------------------+

1. Positive Contrast Media (Radiopaque)

• Mechanism: Positive contrast agents possess high atomic numbers ($Z$) and high physical mass density, which significantly increases the probability of photoelectric absorption of diagnostic X-ray photons compared to soft tissue ($Z_{\ ext{eff}} \approx 7.4$).
• Primary Elements:
  • Iodine ($Z = 53$): Employed for intravascular (IV/IA), intrathecal, body cavity, and gastrointestinal administration. Iodine has a K-edge energy of $33.2 \ ext{ keV}$, which aligns exceptionally well with the average photon energy of diagnostic X-ray beams ($70 \ ext{ to } 90 \ ext{ kVp}$).
  • Barium ($Z = 56$): Employed exclusively in the form of Barium Sulfate ($\ ext{BaSO}_4$) insoluble suspension for oral and rectal gastrointestinal tract evaluation. Barium has a K-edge energy of $37.4 \ ext{ keV}$. Because barium is insoluble and toxic if absorbed into the bloodstream, it must never be administered parenterally or in cases of suspected GI tract perforation.
• Radiographic Appearance: Appears bright white (high radiopacity / density attenuation) on conventional radiograms and digital images.

2. Negative Contrast Media (Radiolucent)

• Mechanism: Negative contrast agents consist of gases with low atomic numbers ($Z \approx 7.6$) and low physical density. They attenuate significantly fewer X-ray photons than surrounding soft tissue, permitting maximum X-ray beam transmission.
• Primary Agents: Room air, Carbon Dioxide ($\ ext{CO}_2$), and Oxygen. $\ ext{CO}_2$ is rapidly absorbed by blood and expired through the lungs, making it an excellent intravascular negative contrast alternative for angiography in patients with severe iodinated contrast allergy or renal failure.
• Radiographic Appearance: Appears dark or black (radiolucent) on radiographs.
• Double-Contrast Techniques: Combining positive (barium or iodine) and negative (air or $\ ext{CO}_2$) agents in mucosal studies (e.g., double-contrast barium enema, double-contrast upper GI series) coats mucosal linings with a thin layer of radiopaque barium while distending the organ lumen with radiolucent air, providing exquisite visualization of mucosal ulcerations and polyps.

---

Classification of Intravascular Iodinated Contrast Media

Intravascular contrast media are classified into three major generations based on their chemical molecular structure, ionic dissociation in solution, and resulting osmolality relative to human blood plasma ($\sim 290 \ ext{ mOsm/kg H}_2\ ext{O}$).

1. High-Osmolar Contrast Media (HOCM) — Ionic Monomers

• Chemical Structure: Formed by a benzene ring tri-iodinated with three iodine atoms at positions 2, 4, and 6, and a carboxyl group ($\ ext{COO}^-$) at position 1, paired with a soluble cation such as sodium ($\ ext{Na}^+$) or meglumine.
• Representative Agents: Diatrizoate (Hypaque, Renografin), Metrizoate, and Iothalamate.
• Dissociation Dynamics: When dissolved in water or blood, each molecule dissociates into 2 active particles: 1 negatively charged anion (containing the 3 iodine atoms) and 1 positively charged cation ($\ ext{Na}^+$ or meglumine). This yields a ratio of 3 iodine atoms to 2 particles (Ratio 1.5).
• Osmolality Range: 1500 to 2000 mOsm/kg $\ ext{H}_2\ ext{O}$, which is approximately 5 to 8 times the osmolality of human blood plasma.
• Clinical Toxicity: The extreme hyperosmolality causes massive fluid shifts from the intracellular and interstitial compartments into the intravascular space. This results in endothelial injury, vascular dilation, sensation of intense heat and pain during injection, hypervolemia, hyperosmolal strain on the myocardium, and a significantly higher incidence of adverse reactions. HOCM is largely obsolete for intravascular injection in modern radiologic practice.

2. Low-Osmolar Contrast Media (LOCM) — Non-Ionic Monomers & Ionic Dimers

Introduced to decrease the severe osmotic effects of HOCM while retaining diagnostic iodine opacity.

• Non-Ionic Monomers:
  • Chemical Structure: Replaces the hydrophilic carboxyl group of the tri-iodinated benzene ring with non-ionizing hydrophilic hydroxyl/amide group attachments.
  • Representative Agents: Iohexol (Omnipaque), Iopamidol (Isovue), Ioversol (Optiray), and Iopromide (Ultravist).
  • Dissociation Dynamics: Does not dissociate in aqueous solution. Each dissolved molecule remains as 1 single particle containing 3 iodine atoms, yielding a ratio of 3 iodine atoms to 1 particle (Ratio 3.0).
  • Osmolality Range: 600 to 800 mOsm/kg $\ ext{H}_2\ ext{O}$, approximately 2 to 3 times the osmolality of blood plasma.
• Ionic Dimers:
  • Representative Agent: Ioxaglate (Hexabrix). Combines two tri-iodinated benzene rings with a single carboxyl group, yielding 6 iodine atoms per 2 dissociated ions (Ratio 3.0) with an osmolality of $\sim 600 \ ext{ mOsm/kg H}_2\ ext{O}$.
• Clinical Safety: Non-ionic LOCM reduces vascular heat, pain, endovascular injury, and overall systemic adverse reaction rates by nearly 5-fold compared to HOCM.

3. Isosmolar Contrast Media (IOCM) — Non-Ionic Dimers

• Chemical Structure: Formed by linking two non-ionic tri-iodinated benzene rings together without carboxyl groups.
• Representative Agent: Iodixanol (Visipaque).
• Dissociation Dynamics: Does not dissociate in solution. Each molecule contains 6 iodine atoms per 1 intact non-dissociating molecule (Ratio 6.0).
• Osmolality Range: 290 mOsm/kg $\ ext{H}_2\ ext{O}$, which is isosmolar (equal) to human blood plasma.
• Clinical Applications: Provides the highest safety profile for patients with severe pre-existing renal impairment, diabetes mellitus, cardiovascular instability, or high-risk intra-arterial interventional procedures.

---

Physical & Chemical Properties of Contrast Agents

The performance and physiological tolerance of iodinated contrast media are dictated by four fundamental physical and chemical parameters:

1. Osmolality

Osmolality measures the number of milliosmoles of active solute particles per kilogram of solvent ($\ ext{mOsm/kg H}_2\ ext{O}$). Hyperosmolar fluids attract water across cell membranes via osmosis. When hyperosmolar contrast is injected into blood vessels, red blood cells creneate (shrink), vascular endothelial cells dehydrate, and circulating blood volume rapidly expands, causing transient vasodilation followed by systemic hypertension, fluid overload, and renal tubular damage.

2. Viscosity

Viscosity describes the fluid's internal friction and resistance to flow, measured in centipoise ($\ ext{cP}$).

• Influencing Factors: Molecular weight, chemical structure (dimers are more viscous than monomers), and iodine concentration. Higher iodine concentrations possess higher viscosity.
• Temperature Dependence: Viscosity is inversely proportional to temperature. Warming contrast media to body temperature ($37^\circ\ ext{C}$ / $98.6^\circ\ ext{F}$) using a calibrated contrast warming sleeve reduces viscosity by approximately 45% to 50%.
• Clinical Significance: Warmed contrast flows smoothly through small-gauge IV catheters (e.g., 20G or 22G) and lowers injection pressure limits on automatic high-pressure injectors during high-flow angiographic runs.

3. Iodine Concentration

Expressed as milligrams of iodine per milliliter of solution ($\ ext{mg I/mL}$, e.g., $300 \ ext{ mg I/mL}$, $350 \ ext{ mg I/mL}$, $370 \ ext{ mg I/mL}$). Higher iodine concentration yields greater X-ray attenuation and higher image contrast enhancement, but simultaneously increases osmolality, viscosity, and potential tissue toxicity.

4. Chemical Toxicity

Chemotoxicity relates to the chemical structure of the agent, including lipid solubility, binding capacity to blood proteins, and displacement of vital electrolytes such as calcium. Non-ionic formulations exhibit markedly lower chemotoxicity than ionic compounds.

---

Classification of Intravascular Contrast Agents

---

Renal Safety & Contrast-Induced Nephropathy (CIN)

1. Definition of Contrast-Induced Nephropathy (CIN)

Contrast-Induced Nephropathy (CIN)—also termed Contrast-Induced Acute Kidney Injury (CI-AKI)—is an acute decline in renal function occurring within 24 to 72 hours following intravascular administration of iodinated contrast media, after excluding other alternative etiologies. It is defined clinically by:

• An absolute increase in serum creatinine of $\ge 0.5 \ ext{ mg/dL}$ ($\ge 44 \ \mu\ ext{mol/L}$), OR
• A relative percentage increase in serum creatinine of $\ge 25%$ from baseline values.

2. Baseline Laboratory Metrics & Thresholds

Before administering IV or IA iodinated contrast, the technologist must verify recent baseline kidney function lab values:

• Serum Creatinine (sCr): Normal reference range is $0.6 \ ext{ to } 1.2 \ ext{ mg/dL}$ ($53 \ ext{ to } 106 \ \mu\ ext{mol/L}$). Values above $1.5 \ ext{ mg/dL}$ indicate baseline renal insufficiency.
• Estimated Glomerular Filtration Rate (eGFR): The primary clinical index for renal clearance:
  • eGFR $> 60 \ ext{ mL/min/1.73m}^2$: Normal kidney function; standard contrast administration carries negligible CIN risk.
  • eGFR $45 \ ext{ to } 59 \ ext{ mL/min/1.73m}^2$: Mildly decreased renal function; low CIN risk.
  • eGFR $30 \ ext{ to } 44 \ ext{ mL/min/1.73m}^2$: Moderate renal failure; increased CIN risk. Requires clinical evaluation, pre-procedure hydration, and minimization of contrast volume.
  • eGFR $< 30 \ ext{ mL/min/1.73m}^2$: Severe renal failure / stage 4 chronic kidney disease. High risk of CIN; iodinated contrast is contraindicated unless diagnostic benefit strictly outweighs life-threatening risk.

3. Hydration Protocols for CIN Prevention

Intravenous volume expansion with isotonic $0.9%$ Normal Saline ($1.0 \ ext{ to } 1.5 \ ext{ mL/kg/hour}$) initiated 6 to 12 hours prior to and continued 6 to 12 hours after contrast administration represents the single most effective, evidence-based strategy to prevent CIN. Hydration dilutes intravascular contrast, preserves renal blood flow, and accelerates renal excretion.

4. Metformin (Glucophage) Management Guidelines

Metformin is an oral biguanide antihyperglycemic agent prescribed for Type 2 diabetes mellitus. Metformin itself is not nephrotoxic. However, if contrast administration induces CIN, impaired renal excretion of metformin leads to drug accumulation and life-threatening metformin-associated lactic acidosis.

• ACR Metformin Protocol:
  1. For patients with eGFR $> 60 \ ext{ mL/min/1.73m}^2$ and no acute kidney injury, metformin does not need to be stopped prior to contrast and no follow-up renal function testing is required.
  2. For patients with eGFR $< 60 \ ext{ mL/min/1.73m}^2$, acute kidney injury, or undergoing intra-arterial contrast administration, metformin must be withheld at the time of or prior to the contrast procedure, and held for 48 hours post-procedure.
  3. Metformin may only be restarted after 48 hours once follow-up laboratory testing confirms that renal function (sCr / eGFR) remains stable at baseline levels.